EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies

De-Yu Li, Xin Liu, Jing-Yi Huang, Wen-Lu Hang, Gu-Ran Yu, Yong Xu iD

Therapeutic Advances in Respiratory Disease · 2024

DOI: 10.1177/17534666241232561 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2024. Verfasst von De-Yu Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NATCM’s Project of High-level Construction of Key TCM Disciplines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nintedanib and pirfenidone are preferred pharmacological therapies for patients with idiopathic pulmonary fibrosis (IPF). However, evidence favoring antifibrotic therapy in patients with non-IPF fibrosing interstitial lung diseases (ILD) is limited.

Objective

To investigate the effects of antifibrotic therapy on disease progression, all-cause mortality, and acute exacerbation (AE) risk in patients with non-IPF fibrosing ILDs.

Design

Meta-analysis. Data sources and methods: Electronic databases were searched for articles published before 28 February 2023. Studies that evaluated the efficacy of antifibrotic agents in patients with fibrosing ILDs were selected. The primary outcome was the disease progression risk, and the secondary outcomes included all-cause mortality and AE risk. The GRADE criteria were used for the certainty of evidence assessment.

Results

Nine studies with 1990 participants were included. Antifibrotic therapy reduced the rate of patients with disease progression (five trials with 1741 subjects; relative risk (RR), 0.56; 95% CI, 0.42–0.75; p < 0.0001; I 2 = 0; high-certainty evidence). Antifibrotic therapy did not significantly decrease all-cause mortality (nine trials with 1990 subjects; RR, 0.76; 95% CI, 0.55–1.03; p = 0.08; I 2 = 0; low-certainty evidence). However, in patients with progressive fibrosing ILDs (PF-ILD), antifibrotic therapy decreased all-cause mortality (four trials with 1100 subjects; RR, 0.69; 95% CI, 0.48–0.98; p = 0.04; I 2 = 0; low-certainty evidence).

Conclusion

Our study supports the use of antifibrotic agents in patients with PF-ILDs, which could slow disease progression and decrease all-cause mortality.

Trial registration

This study protocol was registered with PROSPERO (registration number: CRD42023411272).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialIdiopathic Pulmonary FibrosisHumansAntifibrotic AgentsProspective StudiesDisease ProgressionRandomized Controlled Trials as TopicFibrosis

Stichwörter der Autor:innen

antifibrotic therapydisease progressionfibrosing interstitial lung diseasemeta-analysismortality

Substanzen

Antifibrotic Agents

Autor:innen und Institutionen

  • Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
  • Baoshan Branch, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Respiratory Medicine, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing 210029, China.
  • School of Chinese Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210046, China.

ORCID-Profile: Yong Xu

Förderung

  • NATCM’s Project of High-level Construction of Key TCM Disciplines

Zitieren

APA

Li, D. Y., Liu, X., Huang, J. Y., Hang, W. L., Yu, G. R., & Xu, Y. (2024). Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666241232561

Vancouver

Li DY, Liu X, Huang JY, Hang WL, Yu GR, Xu Y. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies. Therapeutic Advances in Respiratory Disease. 2024. doi:10.1177/17534666241232561

BibTeX
@article{Li2024,
  author = {Li, De-Yu and Liu, Xin and Huang, Jing-Yi and Hang, Wen-Lu and Yu, Gu-Ran and Xu, Yong},
  title = {Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2024},
  doi = {10.1177/17534666241232561}
}
Kostenlos starten →